RxDoctor Payments Data

Madhuri Kasireddy, MD

Internal Medicine · Tyler, TXNPI 1770986424

Payments from drug & device makers

$3,797in general payments, 2019–2025

Across 216 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$673
  • AbbVie$439
  • GSK$428
  • AstraZeneca$388
  • Pfizer$331
  • Otsuka America Pharmaceutical, Inc.$238
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,74899%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,797 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$36,504
Medicare patients
111
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$34,522
JardianceEmpagliflozin36$32,008
JanuviaSitagliptin Phosphate23$16,219
XareltoRivaroxaban14$12,640
Venlafaxine Hcl ErVenlafaxine Hcl21$2,496
Albuterol Sulfate HfaAlbuterol Sulfate47$1,530
Famotidine35$965
Gabapentin55$881
Atorvastatin Calcium99$829
Levothyroxine Sodium90$805
Buspirone Hcl41$772
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$727
Losartan Potassium41$616
Potassium Chloride41$614
Esomeprazole Magnesium17$607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$673$34,52235 claims
Boehringer IngelheimJardiance$31$32,00836 claims
MerckJanuvia$25$16,21923 claims
Johnson & JohnsonXarelto$17$12,64014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →